Overall rank by patents
#48,984
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Nektium Pharma S.l.
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2018–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
5
Total patents granted
3
CPC technology areas
15.6
Avg claims per patent
+300%
5-year filing velocity
The verdict
Nektium holds 5 US patents across 3 technology areas, rank #48,984 of 50,000 tracked assignees.
- #48,984
- of 50,000 US assignees by volume
- Top 87%
- by Innovation Score (23.9/100)
- 15.6
- avg claims per patent
- +300%
- filing velocity, last 5 yrs
Portfolio overview
Nektium Pharma S.l. has been granted 5 US utility patents between 2018 and 2022, placing Nektium Pharma S.l. at rank #48,984 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.6 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Nektium Pharma S.l. is one of the more focused assignees in the PatentsView dataset. By volume, Nektium sits between NEC Hong Kong Limited (5 patents, rank #48,980) and Neosurgical Limited (5 patents, rank #48,988) - the closest US assignees by grant volume. The composite Innovation Score of 23.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 1 in the 2015–2019 window, a +300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Nektium Pharma S.l.'s 15.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Nektium Pharma S.l. against peers pursuing similar technology classes.
Who files at Nektium's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- NEC Hong Kong
NEC Hong Kong Limited
5 patents
- NEC Infrontia
NEC INFRONTIA CORPORATION
5 patents
- Needstomatch
NEEDSTOMATCH CORPORATION
5 patents
- Nefab AB
NEFAB AB
5 patents
- Nellone Therapeut…
NELLONE THERAPEUTICS, INC.
5 patents
- NEMO Arms
NEMO Arms, Inc.
5 patents
- NEO G
NEO G LIMITED
5 patents
- Neosurgical
NEOSURGICAL LIMITED
5 patents
- Nektium Pharma S L ◀
NEKTIUM PHARMA S.L.
5 patents
What this shows Nektium holds 5 patents at rank #48,984, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Nektium
By rank, the assignees closest to #48,984 in granted patent volume.
- NEC Hong Kong Limited #48,980 · 5 patents
- NEC Infrontia Corporation #48,981 · 5 patents
- Needstomatch Corporation #48,982 · 5 patents
- Nefab AB #48,983 · 5 patents
- Nellone Therapeutics, Inc. #48,985 · 5 patents
- NEMO Arms, Inc. #48,986 · 5 patents
- NEO G Limited #48,987 · 5 patents
- Neosurgical Limited #48,988 · 5 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Nektium's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Nektium's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
24 Top 87% higher than 13% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 20.0% |
| 2020 | 2 | 40.0% |
| 2021 | 1 | 20.0% |
| 2022 | 1 | 20.0% |
Which technologies does Nektium Pharma S.l. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Nektium Pharma S.l. hold?
Nektium Pharma S.l. holds 5 US granted patents filed between 2018 and 2022, spanning 3 technology areas.
What is Nektium Pharma S.l.'s Innovation Score?
Nektium Pharma S.l. has an Innovation Score of 23.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Nektium Pharma S.l. focus on?
Nektium Pharma S.l.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 5 patents. The company has filed patents in 3 CPC subclasses total.
Is Nektium Pharma S.l.'s patent filing rate increasing or decreasing?
Nektium Pharma S.l.'s recent filing velocity is +300% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Nektium Pharma S.l.'s patents?
Nektium Pharma S.l.'s patents average 15.6 claims each. This falls within the standard range, providing solid legal coverage.
How is the Nektium Pharma S.l. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Nektium's 5 grants land it in the top 87% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Nektium ranks #48,984 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.